Table 4.
Comparison of the primary outcomes between the first- and second-line treatments in the included studies
| ORR | DCR | PFS-16w | OS-12 m | OS-6 m | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | 95% CI | n | 95% C | n | 95% C | n | 95% C | n | 95% C | |
| Overall | 342 | 0.126 (0.063,0.190) | 221 | 0.603 (0.473,0.733) | 221 | 0.502 (0.382,0.622) | 298 | 0.437 (0.329,0.546) | 298 | 0.739 (0.664,0.813) |
| First line | 162 | 0.103 (0.015,0.191) | 51 | 0.530 (0.393,0.667) | 51 | 0.353 (0.222,0.484) | 162 | 0.408 (0.332,0.483) | 162 | 0.703 (0.633,0.773) |
| Second line | 180 | 0.145 (0.044,0.247) | 170 | 0.620 (0.465,0.775) | 170 | 0.545 (0.433,0.656) | 136 | 0.443 (0.243,0.644) | 136 | 0.757 (0.632,0.882) |
| P values | 0.089 | 0.174 | 0.012 | 0.048 | 0.050 | |||||
Note: Grade 3–4 AEs was obtained by adding all the adverse events in grade 3–4 together. ORR objective response rate, DCR disease control rate, PFS-16w progression-free survival rate at 16 weeks, OS-12 m overall survival rate at 12 months; OS-6 m overall survival rate at 6 months